前沿生物：FB7013临床试验申请获受理

Core Viewpoint - The company has submitted a clinical trial application for its self-developed siRNA drug FB7013 targeting the MASP-2 protein, which is intended for the treatment of primary immunoglobulin A nephropathy (IgA nephropathy) [1] Group 1 - The clinical trial application was submitted to the National Medical Products Administration on December 22, 2025, and the acceptance notice was received on December 31, 2025 [1] - FB7013 is the world's first siRNA drug targeting the MASP-2 protein to apply for clinical trials, indicating its potential as a first-in-class treatment [1]